May 13 (Reuters) - Britain's GSK (GSK.L), opens new tab and drug developer iTeos Therapeutics (ITOS.O), opens new tab said on Tuesday they have stopped developing an experimental lung cancer drug ...

TIGIT-targeting therapies have largely disappointed in recent months, with failed studies, terminated partnerships and ...

The mechanism has proven challenging, with GSK and iTeos becoming the latest companies to terminate an anti-TIGIT asset. Last month, BeiGene announced it was terminating development of ociperlimab ...

GSK decided to axe the candidate, which it paid iTeos $625m for in a rights deal in 2021. A further $1.45bn in milestone payments were also on the table, though hopes of those diminished after the ...

GSK and iTeos dealt a further blow to the mechanism on Tuesday after reviewing results from phase 2 trials. One study was testing belrestotug in combination with anti-PD-1 checkpoint inhibitor ...

iTeos and GSK terminate belrestotug program after GALAXIES Lung-201 results fail to show significant progression-free survival improvements. Quiver AI Summary.

iTeos Therapeutics has said it is evaluating with partner GlaxoSmithKline whether to conduct additional clinical trials of TIGIT drug EOS-448 following the failure of a key trial for Roche's rival ...

GlaxoSmithKline has staked a claim to the fast-moving category of cancer therapies targeting the TIGIT immune checkpoint, agreeing a $2 billion plus licensing agreement with iTeos Therapeutics for ...

– GALAXIES Lung-201 did not meet established criteria for clinically meaningful improvements in progression free survival – Based on totality of data, iTeos and GSK have agreed to terminate ...

Shares in iTeos Therapeutics surged after the company said it would wind down operations. The stock was up 27% at $10.87 in premarket trading. Shares were already up 11% year-to-date when the ...

GSK and iTeos are the latest companies to scrap a jointly developed anti-TIGIT drug after it failed to demonstrate a meaningful benefit in two Phase II trials. Belrestotug, a human IgG1 antibody ...